BCM
TEVA icon

Beck Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Beck Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-4,245
Closed -$223K – 169
2014
Q2 		$223K Sell
4,245
-225
-5% -$11.5K 0.15% 143
2014
Q1 		$237K Buy
+4,470
New +$207K 0.18% 130

Other funds holding TEVA

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACM
Americafirst Capital Management Roseville, California $74M AUM 13.49% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Lazard Asset Management
Lazard Asset Management New York $60.8B AUM 22.47% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Beck Capital Management's TEVA Position: Q3 2014 in Review

Beck Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2014, closing a stake of 4,245 shares — an estimated $223K sold.

Beck Capital Management first reported a position in TEVA in Q1 2014 and held it in 2 quarters. The position peaked at $237K in Q1 2014. 772 funds tracked by Wall St. Rank hold TEVA as of Q3 2014.

  • Beck Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Beck Capital Management sold 4,245 Teva Pharmaceuticals shares in Q3 2014, an estimated $223K.
  • Beck Capital Management first reported a position in Teva Pharmaceuticals in Q1 2014 and held it in 2 quarters.
  • Beck Capital Management's Teva Pharmaceuticals position peaked at $237K in Q1 2014.
  • 772 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2014.

Based on Beck Capital Management's 13F filing for Q3 2014, filed 13 Nov 2014.